Literature DB >> 12638673

Heparin-induced thrombocytopenia with associated thrombosis in children after the Fontan operation: report of two cases.

Rosalia Porcelli1, Bonnie C Moskowitz, Frank Cetta, Lynn C Graham, John E Godwin, Benjamin W Eidem, M Margaret Prechel, Jeanine M Walenga.   

Abstract

Heparin-induced thrombocytopenia is a widely recognized clinical disorder. The spectrum of disease ranges from clinically insignificant to severe thrombosis (heparin-induced thrombocytopenia with associated thrombosis). Overall, thrombosis occurs in approximately 33% of adults diagnosed with heparin-induced thrombocytopenia and has been associated with high morbidity and mortality rates. Diagnostic testing for this disorder is not standard in children with thrombocytopenia who are receiving heparin, despite the fact that children with congenital heart disease may be exposed to heparin frequently. There are few reported cases of heparin-induced thrombocytopenia with associated thrombosis in children; herein, we describe the cases of 2 children who developed this disorder after undergoing a Fontan operation.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12638673      PMCID: PMC152838     

Source DB:  PubMed          Journal:  Tex Heart Inst J        ISSN: 0730-2347


  21 in total

1.  Platelet factor 4 complexed to heparin is the target for antibodies generated in heparin-induced thrombocytopenia.

Authors:  J Amiral; F Bridey; M Dreyfus; A M Vissoc; E Fressinaud; M Wolf; D Meyer
Journal:  Thromb Haemost       Date:  1992-07-06       Impact factor: 5.249

2.  Heparin-induced thrombocytopenia: mechanism of interaction of the heparin-dependent antibody with platelets.

Authors:  B H Chong; I Fawaz; C N Chesterman; M C Berndt
Journal:  Br J Haematol       Date:  1989-10       Impact factor: 6.998

3.  Heparin-induced thrombocytopenia, thrombosis, and hemorrhage.

Authors:  D Silver; D N Kapsch; E K Tsoi
Journal:  Ann Surg       Date:  1983-09       Impact factor: 12.969

4.  Insights into heparin-induced thrombocytopenia.

Authors:  G P Anderson
Journal:  Br J Haematol       Date:  1992-04       Impact factor: 6.998

Review 5.  Heparin-induced thrombocytopenia.

Authors:  J G Kelton
Journal:  Haemostasis       Date:  1986

6.  A diagnostic test for heparin-induced thrombocytopenia.

Authors:  D Sheridan; C Carter; J G Kelton
Journal:  Blood       Date:  1986-01       Impact factor: 22.113

7.  The heparin-induced thrombocytopenia syndrome: an update.

Authors:  J Laster; D Cikrit; N Walker; D Silver
Journal:  Surgery       Date:  1987-10       Impact factor: 3.982

8.  Heparin-associated thrombocytopenia and thrombosis: a serious clinical problem and potential solution.

Authors:  R G Makhoul; C S Greenberg; R L McCann
Journal:  J Vasc Surg       Date:  1986-11       Impact factor: 4.268

9.  Heparin-induced thrombocytopenia in children.

Authors:  I A Murdoch; R M Beattie; D M Silver
Journal:  Acta Paediatr       Date:  1993-05       Impact factor: 2.299

10.  Anti-GPIIb/IIIa (CD41) monoclonal antibody-induced platelet activation requires Fc receptor-dependent cell-cell interaction.

Authors:  G P Anderson; J G van de Winkel; C L Anderson
Journal:  Br J Haematol       Date:  1991-09       Impact factor: 6.998

View more
  3 in total

Review 1.  Heparin-induced thrombocytopenia in paediatrics: clinical characteristics, therapy and outcomes.

Authors:  Lorenz Risch; Joachim E Fischer; Roberto Herklotz; Andreas R Huber
Journal:  Intensive Care Med       Date:  2004-05-19       Impact factor: 17.440

2.  Approach to postoperative fever in pediatric cardiac patients.

Authors:  Ajay K Gupta; Vishal K Singh; Amit Varma
Journal:  Ann Pediatr Cardiol       Date:  2012-01

Review 3.  Platelets and extra-corporeal membrane oxygenation in adult patients: a systematic review and meta-analysis.

Authors:  Federica Jiritano; Giuseppe Filiberto Serraino; Hugo Ten Cate; Dario Fina; Matteo Matteucci; Pasquale Mastroroberto; Roberto Lorusso
Journal:  Intensive Care Med       Date:  2020-04-23       Impact factor: 17.440

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.